USFDA grants priority review to Sanofi-Regeneron Dupixent for bullous pemphigoid
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to
Dupilumab Gets Priority Review for Bullous Pemphigoid
Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority
US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid
US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U
Dupilumab Under FDA Priority Review for Bullous Pemphigoid
Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid
Regeneron and Sanofi on Tuesday said the speedy FDA review is based on study results showing significant improvements in sustained disease remission with Dupixent compared with placebo. The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease,
Too Old to Operate2d
Dupilumab and Airway Imaging in Moderate-to-Severe Type 2 Asthma
The following is a summary of “Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging ...
dermatologyadvisor1d
Dupilumab in Atopic Dermatitis: Favorable Cardiometabolic Profile Confirmed
Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.
Healio13d
Top in allergy/asthma: Dupilumab ineffective for peanut desensitization; asthma blood test
Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind ...
Too Old to Operate15d
Impact of Dupilumab on Skin Protein and Metabolite Composition in AD
The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients treated with dupilumab,” published in the January 2025 issue of Allergy and ...
The Lancet6d
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab
Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...
Healio24d
Dupilumab does not desensitize children with peanut allergy
Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to study results. Image: Adobe Stock ...